The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Zepbound has been a hot seller for the company. If any pharmaceutical producer is going to exploit the full potential of such ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

In a remarkable display of market confidence, HIMS & Hers Health, Inc. (HIMS) stock has soared to an all-time high, reaching ...

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

The top 20 biopharmaceutical companies experienced mixed performance in 2024 amid a dynamic landscape influenced by various ...

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span ...

Zepbound (tirzepatide ... You can check ahead of time to see whether your pharmacy has the drug in stock. You must have a prescription from a doctor to get tirzepatide. As of 2024, tirzepatide ...

Eli Lilly and Company (NYSE:LLY – Get Free Report) had its target price lowered by equities researchers at Citigroup from ...

Akero Therapeutics has hit a home run, reporting statistically significant results in two key 96-week metabolic ...